Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Gary L. Kepler who wrote (9892)	5/11/1999 1:26:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

One thing people tend to forget, I didn't see E5 or any other sepsis hopeful cure 25 out of 26 young ones with Meningo. AND I didn't see any of them reverse effects of septicemia caused by E. Coli in baboons. We still have not answered the riddle of why did we have problems meeting the mortality requirement in Phase III Meningo? Pure guessing on my part BUT I predict zero deaths in treatment group UNLESS severely obese with cardiac abnormalities are in treatment group. Does anyone really know how potent BPI really is? Bob, do you know? Does it REALLY return vascular integrity? How synergistic is it with other antibiotics in treating gram neg infections? Why did the FDA go to Xoma in regard to synergistic effects of BPI? Why did the FDA give Subpart E designation to Xoma in Meningo? Only my opinions.